New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePNC-27 vs TB-500

PNC-27 vs TB-500

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PNC-27
Recovery & Repair
TB-500
Summary
PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in nearly all human and animal cells. It promotes cell migration to injury sites, accelerates tissue regeneration, and reduces chronic inflammation.
Half-Life
Not well established; estimated minutes to hours
2–3 hours
Admin Route
Intravenous (research), Intraperitoneal (research)
SubQ, IM
Research
Typical Dose
Not established for humans; research doses vary by cell line and model
2–2.5 mg
Frequency
Not established for human use
Twice weekly
Key Benefits
  • Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
  • Spares normal cells lacking surface HDM2 expression
  • Membranolytic mechanism bypasses intracellular resistance pathways
  • Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
  • Potential for combination with conventional chemotherapy
  • Novel non-genotoxic anticancer mechanism
  • Enhances muscle tissue regeneration
  • Accelerates healing of wounds and injuries
  • Reduces inflammation and pain
  • Improves flexibility and mobility
  • Promotes new blood vessel formation
  • Supports hair growth and skin health
  • May improve cardiac function after injury
  • Systemic healing effect — works at distance from injection site
Side Effects
  • Limited human clinical data; largely in vitro and animal studies
  • Potential immunogenic reactions (foreign peptide)
  • Systemic toxicity at high doses not well characterized
  • Unknown interactions with current chemotherapy agents
  • Injection site discomfort
  • Fatigue (rare)
  • Headache (rare)
Stacks With